Cigna (CI): analysis in plain words
Is Cigna cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Cigna (CI) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Cigna according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Cigna (CI) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $305.41 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 12.6x | Price over earnings per share |
| Revenue growth | +6.7% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 2.3% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.9x | Years of operating profit to repay debt |
| Dividend yield | 2.11% | Annual dividend over price |
| Market cap | $80.7 billion | What the stock market values it at |
The Cigna figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any CI figure that is not available shows as N/A: we do not estimate it.
How Cigna makes money
The Cigna Group has two main platforms. Evernorth Health Services, the larger by revenue, includes pharmacy benefit manager Express Scripts and specialty pharmacy Accredo, while Cigna Healthcare sells health coverage, mainly to employers insuring their workers. The vast majority of its business is in the United States.
Over the last 12 months, Cigna brought in revenue of $282.4 billion. For every 100 it sells, Cigna keeps 9.1 after the direct cost of what it sells (gross margin) and 4.0 after all operating costs (operating margin). With 65,669 full-time employees, that is about $4 million of revenue per employee.
Cigna against its sector
To know whether a Cigna figure is high or low you have to put it next to similar companies. This table compares Cigna with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Cigna | healthcare and pharma median |
|---|---|---|
| P/E | 12.6x | 31.3x (30) |
| Revenue growth | +6.7% | +8.3% (33) |
| Net margin | 2.3% | 14.9% (33) |
| Dividend yield | 2.11% | 1.52% (33) |
| Net debt / EBITDA | 1.9x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Cigna trades on a lower P/E, grows more slowly and earns a thinner margin. By size, Cigna ranks number 23 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Cigna
What works in favour of Cigna, according to its figures as of November 4, 2026:
- On a P/E basis Cigna trades cheaper than its sector: 12.6x its annual earnings, against 31.3x for the healthcare and pharma median (30 companies with data).
- Cigna generates real cash: $8.0 billion of free cash flow over 12 months, 9.9% of its stock market value.
- Analysts expect Cigna earnings to rise: its P/E on the next 12 months of estimated earnings is 9.1x, below the current 12.6x.
The main risk for Cigna
Cigna runs on a thin net margin (2.3%, against a healthcare and pharma median of 14.9%): a rise in costs can easily wipe out profit.
And, like the rest of healthcare and pharma, Cigna is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Cigna
Is it a good time to buy Cigna stock?
Fintols does not tell you whether to buy or sell Cigna, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Cigna stock trades at $305.41, 3% below its 52-week high ($316.27) and 20% above its low ($255.53). Its P/E is 12.6x against a healthcare and pharma median of 31.3x, and 9.1x on the earnings analysts expect over the next 12 months. With Cigna, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Cigna pay a dividend?
Yes. As of November 4, 2026, Cigna pays $6.24 per share a year, which at today's price is a yield of 2.11%. It uses 25% of its profit to pay it, which leaves room to keep paying it if profit dips. Its average dividend yield over the last five years is 1.73%. The healthcare and pharma median on Fintols is 1.52%.
Is Cigna stock expensive?
It depends on what you compare it with. On P/E, Cigna trades at 12.6x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Cigna is valued at 8.1x its EBITDA (EV/EBITDA). A high P/E alone does not make Cigna expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Cigna's competitors?
On Fintols we compare Cigna with Elevance Health, Zoetis and Regeneron, which are also in healthcare and pharma. As of November 4, 2026, Elevance Health is worth $94.2 billion and trades on a P/E of 18.4; Zoetis is worth $36.9 billion and trades on a P/E of 14.7; Regeneron is worth $96.3 billion and trades on a P/E of 20.6. Each has a side-by-side comparison with Cigna below.
Cigna competitors
- Elevance Health (ELV) analysis · Cigna vs Elevance Health comparison
- Zoetis (ZTS) analysis · Cigna vs Zoetis comparison
- Regeneron (REGN) analysis · Cigna vs Regeneron comparison
To understand Cigna better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Cigna: healthcare and pharma stocks and S&P 500 companies. Open the full CI analysis with its valuation and scenarios. Educational content about Cigna, not investment advice.